B
BVF Partners L.P.
+ 持有XFOR
-6.96%
3個月報酬率
$3.240
+0.072 (+2.21%)收盤時
Loading chart…
- 最高
- 3.360
- 開盤
- 3.300
- 成交量加權均價
- 3.23
- 成交量
- 536.59K
- 市值
- 112.54M
- 最低
- 3.100
- 成交金額
- 1.73M
- 企業價值/稅息折舊攤銷前利潤（TTM）
- -9.90
X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
AI 分析 of X4 Pharmaceuticals Inc (XFOR)
買進X4 Pharmaceuticals Inc is a good buy right now due to its recent positive earnings report showing a revenue increase of 347.2% year-over-year, with a current price of $3.35 significantly below the analyst target of $12. Additionally, the RSI is at 78.67, indicating strong momentum. The main risk is the upcoming earnings report, with an estimated EPS of -0.19, which could impact investor sentiment.
估值指標
X4 Pharmaceuticals Inc（XFOR）目前預期本益比為 0.00，5 年平均預期本益比為 -1.85。
持有 XFOR 的大戶
事件時間軸
資訊
1.011-03NewsfilterX4 Pharmaceuticals to Participate in Multiple Investment Conferences
- 2.010-29Newsfilter
X4 Pharmaceuticals Highlights Market Opportunity and Clinical Progress for Mavorixafor
9.009-08NASDAQ.COMX4 Pharmaceuticals Achieves Positive FDA Meeting Outcome
- 9.009-08Newsfilter
FDA Approves Reduced Sample Size for 4WARD Trial
- 5.009-01Newsfilter
X4 Pharmaceuticals Grants Stock Options to New Employees
XFOR 常見問題 —— 由 Alphio AI 解答
X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
X4 Pharmaceuticals Inc is a good buy right now due to its recent positive earnings report showing a revenue increase of 347.2% year-over-year, with a current price of $3.35 significantly below the analyst target of $12. Additionally, the RSI is at 78.67, indicating strong momentum. The main risk is the upcoming earnings report, with an estimated EPS of -0.19, which could impact investor sentiment.
社群
更多 ↗暫無貼文
註冊或登入後參與討論相關文章
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
- AppLovin Q3 2026 Deep Dive: Beaten-Down S&P Dog Meets Axon Next-Gen Beat-and-Raise—and a $3.2B BuybaAppLovin Q3 2026: $2.185B rev (+55%), EPS $4.30 vs ~$4.03–4.04 Street, Adj EBITDA $1.842B (84%). Beat own guide $100M; Q4 $2.365–2.395B; auth +$3.2B; AH +22–24%.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。